Esther Latres, Ph.D., is Vice President of Research at JDRF. In this role, Esther leads the strategic development of curative therapies for type 1 diabetes. Her work centers on enabling the translation of scientific discoveries into disease modifying and cell replacement therapies for restoring glucose and overall metabolic control, which will contribute to better treatments and a cure for T1D. Additionally, her team leads JDRF’s goal to increase access to T1D risk screening and monitoring by expanding programs that will identify at risk individuals who could be protected from the consequences of losing beta cell function due to autoimmunity, and benefit from disease modifying therapies once approved. Prior to joining JDRF in 2015, Esther developed her scientific career at Regeneron Pharmaceuticals, where she led discovery and research of therapeutic candidates to treat skeletal muscle and metabolic diseases, some of which have advanced into clinical trials. She is the author on numerous publications and co-inventor on several patents. Esther received a Ph.D. in biochemistry and molecular biology at the University of Barcelona and has received postdoctoral training and held research positions at Sloan-Kettering Cancer Center, Bristol-Myers Squibb Institute and New York University Medical Center.